Back to Journals » International Journal of Nanomedicine » Volume 12

Development of gold nanoparticles coated with silica containing the antibiofilm drug cinnamaldehyde and their effects on pathogenic bacteria

Authors Ramasamy M, Lee JH, Lee J

Received 19 January 2017

Accepted for publication 10 March 2017

Published 6 April 2017 Volume 2017:12 Pages 2813—2828

DOI https://doi.org/10.2147/IJN.S132784

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Thomas Webster


Mohankandhasamy Ramasamy, Jin-Hyung Lee, Jintae Lee

School of Chemical Engineering, Yeungnam University, Gyeongsan, Republic of Korea

Abstract: Emerging resistance to antibiotics is a mounting worldwide health concern and increases the need for nonantibiotic strategies to combat infectious diseases caused by bacterial pathogens. In this study, the authors used the antibiofilm activity of the naturally occurring antimicrobial cinnamaldehyde (CNMA) conjugated to the surface of gold nanoparticles (GNPs) to deliver CNMA efficiently and eradicate biofilms of Gram-negative organisms (enterohemorrhagic Escherichia coli O157:H7, and Pseudomonas aeruginosa), Gram positive (methicillin-sensitive Staphylococcus aureus organisms, and methicillin-resistant Staphylococcus aureus) bacteria. CNMA-GNPs containing 0.005% (v/v) of CNMA were found to inhibit biofilm formation efficiently. The distributions of nanoparticles in biofilm cells and their biofilm disruption activities, including distorted cell morphology, were determined by transmission electron microscopy. In addition to their antibiofilm activities, CNMA-GNPs attenuated S. aureus virulence and protected Caenorhabditis elegans (C. elegans) worms. Here, the authors report the antibiofilm effects of CNMA-GNPs and suggest that they could be used to treat pathogenic bacterial infections in vivo.

Keywords: antibiofilm, biocompatible, Caenorhabditis elegans, cinnamaldehyde, gold nanoparticles, Staphylococcus aureus

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]